Spravato is now the first stand-alone therapy for treatment-resistant depression, for patients who haven’t responded to oral ...

Intra-Cellular Therapies makes Caplyta, a once-daily pill for adults with schizophrenia and bipolar-related depression ...

Johnson & Johnson (NYSE:JNJ), a global healthcare giant, continues to navigate a complex landscape of opportunities and ...

Johnson & Johnson, founded in 1886, makes and sells medical devices, pharmaceuticals, and consumer health products. Headquartered in New Brunswick, N.J., the company operates over 250 subsidiary ...

Analyst Tim Anderson of Bank of America Securities reiterated a Hold rating on Johnson & Johnson (JNJ – Research Report), reducing the ...

Johnson & Johnson “should have known that the J&J Products contained harmful, deleterious, carcinogenic and inherently dangerous asbestos dust and fibers” and the products reportedly did not ...

In a report released today, Terence Flynn from Morgan Stanley maintained a Hold rating on Johnson & Johnson (JNJ – Research Report), with a ...

Johnson & Johnson's Q4 2024 earnings missed EPS expectations, but broadly met revenue targets. Click here to read why JNJ ...

Sales across other products were only down 1%. In 2020 and 2021 (albeit to a lesser degree in 2021), Johnson and Johnson benefitted from some unique, one-time tax benefits. These benefits did not ...

In 2021, Johnson & Johnson unveiled a plan to spin off its consumer products division to focus on pharmaceuticals and medical technology. The company completed the Kenvue spinoff to shareholders ...

The global bone growth products market report includes exclusive data on 30 vendors. The market is highly competitive, with global players like Medtronic, Johnson & Johnson, Stryker, and Zimmer ...